Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233324 | 0.82 | GRN (0.46) | TGFBR1ALDH1A1GRNSORT1ALPL | |
| SCHEMBL23730611 | 0.78 | SMN1; SMN2 (0.39) | TGFBR1ALDH1A1GRNSORT1CTSL | |
| SCHEMBL13878788 | 0.74 | CA14 (0.41) | ALDH1A1IMPDH2IMPDH1POLB | |
| SCHEMBL4224895 | 0.74 | CA14 (0.41) | ALDH1A1IMPDH2IMPDH1POLB | |
| SCHEMBL16406515 | 0.74 | CA2 (0.34) | TGFBR1ALDH1A1GRNSORT1POLB | |
| SCHEMBL3049273 | 0.74 | CTSK (0.47) | CTSLCTSBCTSSCA1CA2 | |
| SCHEMBL17070598 | 0.74 | CTSS (0.40) | ALDH1A1CTSLCTSBCTSSCA1 | |
| SCHEMBL2367410 | 0.74 | CTSK (0.47) | CTSLCTSBCTSSCA1CA2 | |
| SCHEMBL20739435 | 0.74 | CA1 (0.35) | TGFBR1GRNSORT1POLBCTSL | |
| SCHEMBL27695095 | 0.69 | TSHR (0.35) | GRNSORT1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | TGFBR1 2418/4885ALDH1A1 3177/4885IMPDH2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.